Wellington Management Group LLP raised its position in Artivion, Inc. (NYSE:AORT – Free Report) by 5.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,396,731 shares of the company’s stock after purchasing an additional 121,476 shares during the quarter. Wellington Management Group LLP owned approximately 0.06% of Artivion worth $31,397,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Money Concepts Capital Corp bought a new stake in shares of Artivion during the 4th quarter worth about $28,000. Quadrant Capital Group LLC bought a new stake in shares of Artivion during the 4th quarter worth about $31,000. Captrust Financial Advisors bought a new stake in shares of Artivion during the 2nd quarter worth about $39,000. State of Wyoming boosted its stake in shares of Artivion by 207.1% during the 4th quarter. State of Wyoming now owns 3,495 shares of the company’s stock worth $42,000 after acquiring an additional 2,357 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its stake in shares of Artivion by 54.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 3,859 shares of the company’s stock worth $47,000 after acquiring an additional 1,353 shares in the last quarter. Hedge funds and other institutional investors own 83.32% of the company’s stock.
Artivion Price Performance
NYSE AORT opened at $15.72 on Friday. Artivion, Inc. has a twelve month low of $9.64 and a twelve month high of $22.45. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.30 and a current ratio of 4.69. The stock has a market capitalization of $645.15 million, a PE ratio of -22.46 and a beta of 1.39. The stock has a 50-day simple moving average of $16.55 and a 200 day simple moving average of $14.89.
Wall Street Analysts Forecast Growth
Separately, Needham & Company LLC reiterated a “buy” rating and set a $26.00 price target on shares of Artivion in a research note on Friday, August 4th.
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo.
- Five stocks we like better than Artivion
- Trading Stocks: RSI and Why it’s Useful
- These 3 Wood Stocks are about to go on Discount
- Why Are Stock Sectors Important to Successful Investing?
- Same Coin, Different Sides: 2 Observability Stocks Reverse Ways
- What is Forex and How Does it Work?
- 3 Stocks Awaiting Winter Winds of Opportunity
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.